Preparation of Syngeneic Tumor Regressor Serum Reactive

with the Unique Determinants of the Abelson Murine

Leukemia Virus-Encoded P120 Protein at the Cell Surface by Witte, O. N. et al.
JouRNAL OF VIROLOGY, Sept. 1979, p. 776-784 
0022-538X/79/09-0776/09$02.00/0 
Vol.3l,No.3 
Preparation of Syngeneic Tumor Regressor Serum Reactive 
with the Unique Determinants of the Abelson Murine 
Leukemia Virus-Encoded P120 Protein at the Cell Surface 
0. N. WITTE,' N. ROSENBERG/ AND D. BALTIMORE'* 
Department of Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, 
Massachusetts 02139, 1 and Cancer Research Center, Tufts University School of Medicine, Boston, 
Massachusetts 021112 
Received for publication 30 March 1979 
Antisera reactive with the Abelson murine leukemia virus (A-MuLV)-specified 
P120 (anti-AbT sera) were produced in C57L/ J mice. Of many strains tested, only 
C57L/J reproducibly rejected syngeneic A-MuLV-induced tumor cells; after 
multiple immunizations their sera would immunoprecipitate both P120 and 
Moloney-MuLV (M-MuLV) proteins. Using labeled A-MuLV-induced nonpro-
ducer cells, only P120 could be detected by anti-AbT sera, suggesting that it may 
be the only A-MuLV-specified protein. Reactivity of anti-AbT sera with P120 
was not blocked by M-MuLV virion proteins, implying that the sera recognize a 
portion of P120 that is not homologous to any M-MuLV product. Anti-AbT sera 
stained the surface oflive, A-MuLV-transformed nonproducer cells in a two-stage 
immunofluorescence assay, and such staining was not blocked by M-MuLV 
protein. Also, intact A-MuLV-transformed cells absorbed much of the reactivity 
of certain anti-AbT sera for P120. Thus a portion of P120 appears to be exposed 
on the surface of transformed cells. P120 lacks detectable carbohydrate, is not 
affected by endoglycosidase H, and cannot be labeled by lactoperoxidase-cata-
lyzed iodination. Thus P120 is an unusual surface protein. 
Abelson murine leukemia virus (A-MuLV) is 
a defective, transforming retrovirus isolated 
from a corticosteroid-treated BALB/c mouse 
that had been inoculated with the replication-
competent virus, Moloney MuLV (M-MuLV) 
(1). A-MuLV has unique biological and biochem-
ical properties that distinguish it from its parent 
virus: Most importantly, A-MuLV transforms a 
different class of hematopoietic target cells from 
M-MuLV (9-11, 13, 17, 18, 21-23), and A-MuLV 
is capable of transforming fibroblastic cells (19). 
A-MuLV, like other defective, transforming ret-
roviruses, requires a helper virus (like M-MuL V) 
to provide its structural proteins and its enzy-
matic functions for replication (5, 27). 
A-MuLV RNA is 5,600 bases long and shares 
sequence homology with M-MuLV at its 5' and 
3' ends (A. Shields, Ph.D. thesis, Massachusetts 
Institute of Technology, Cambridge, 1979). A 
single stretch of 3,600 nucleotides of sequence 
not derived from M-MuLV fills the center of the 
A-MuLV genome. 
and a portion of p30-fuseq to a region of ap-
proximately 90,000 molecular weight derived 
from the A-MuLV unique sequences. 
In an attempt to make an antiserum that 
might recognize the unique (non-M-MuLV) de-
terminants on the A-MuLV P120, we have used 
the one case we could fmd in which mice would 
reproducibly reject a syngeneic A-MuLV-trans-
formed cell line. Because xenogeneic sera from 
animals that have rejected Rous sarcoma virus-
induced tumors have been so useful in defming 
the transforming protein of that virus (3, 12), it 
seemed possible that syngeneic immunization 
with A-MuLV-induced tumors would be simi-
larly useful. Risser et al. ( 16) have already shown 
the utility of this approach in their description 
of an A-MuLV-related cell surface antigen de-
tected by antibody-mediated cytotoxity. We 
have prepared sera that precipitate P120 via its 
unique determinants and have used the sera in 
a two-stage immunofluorescence assay to detect 
an A-MuLV-specific cell surface antigen. 
The only known protein encoded by the A-
MuLV genome is one of 120,000 molecular MATERIALS AND METHODS 
weight called P120 (14, 29). This protein con- Cell lines. A-MuLV-transformed BALB/c lymph-
tains serological determinants of the M-MuLV oid cell lines 2M3 (nonproducer) and 2M3/M (pro-
amino-terminal gag gene products-p15, p12, ducer of A-MuLV and M-MuLV), C57L/J lymphoid 
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cell line L1 and subclone L1-2, nonproducer NIH 
mouse fibroblast line A2, and rat cell line Ab-NRK 
have been previously described (17, 29). 
Cell labeling and immunoprecipitation. All ra-
dioactive chemicals were purchased from New Eng-
land Nuclear Corp., Boston, Mass. Cells were labeled 
with [35S]methionine (50 I'Ci/ml) or [3H]leucine (200 
I'Ci/ml) in medium containing 1/100 the normal me-
thionine or 1/50 the normal leucine concentration, 
respectively. Cells were pulse-labeled (30 min) with 
14C-mixed amino acids (25 I'Ci/ml) in balanced salt 
solution with glucose or were labeled in complete 
medium with D-[3H]glucosamine at 100 I'Ci/ml. 
Cells were iodinated by two techniques. Lactoper-
oxidase-catalyzed iodination at room temperature was 
performed as previously described (30) employing 500 
1-1Ci of Na 1251 per 107 cells, with 50"' of lactoperoxidase 
(Calbiochem, grade B). Specific activities were 107 to 
3 x 107 cpm/107 cells. Iodination by 1251-labeled Bolton 
Hunter reagent was performed at 0°C. Cells (lOS to 2 
x 107) were washed with phosphate-buffered saline 
(pH 7.5), then resuspended in 1 ml of phosphate-
buffered saline with 50 to 75 1-1Ci of Bolton-Hunter 
reagent for 30 min. Cells were washed with phosphate-
buffered saline, and excess reagent was quenched with 
glycine. Specific activities were 3 X 107 to 7 X 107 cpm/ 
107 cells. 
Labeled cells were extracted and clarified for im-
munoprecipitation as previously described (28, 29). 
Routinely, 107 labeled cells were extracted into 5 ml of 
lysis buffer (10 mM NaH2PO.-Na2HPO., pH 7.5; 100 
mM NaCl; 1% Triton X-100; 0.5% sodium deoxycho-
late; 0.1% sodium dodecyl sulfate) at ooc and clarified 
at 150,000 X g for 3 h. One-milliliter fractions. were 
precipitated with normal or immune serum. Samples 
were analyzed by electrophoresis through 10% poly-
acrylamide-sodium dodecyl sulfate gels developed by 
fluorography (2, 7, 8). Films were exposed for 2 to 3 
days. 
Antisera used included rabbit anti-M-MuLV re-
verse transcriptase/p15, rabbit anti-M-MuLV gp70, 
and goat anti-M-MuLV virions, which have been pre-
viously described (28, 29). 
Membrane immunofluorescence. All sera and 
media employed were filtered through 0.2-l'm filters or 
clarified at 100,000 X g for 2 h before use to remove 
aggregates. Viable cells (2 X 1<f) were washed twice in 
RPMI-1640 with 10% heat-inactivated fetal calf serum 
and suspended at 0°C in 50 !'I of normal serum or 
antiserum for 45 min. Cells were washed by sedimen-
tation through heat-inactivated fetal calf serum, re-
suspended, and washed with RPMI-10% heat-inacti-
vated fetal calf serum. Pretitrated dilutions of fluores-
cein-conjugated second-stage antibody (goat anti-
mouse immunoglobulin G or goat anti-rabbit immu-
noglobulin G; Meloy Labs, Springfield, Va.) were 
mixed with cells for 45 min at 0°C. The cells were 
washed as above and suspended in RPMI-10% heat-
inactivated fetal calf serum to view as wet mounts or, 
alternatively, in phosphate-buffered saline-50% heat-
inactivated fetal calf serum to prepare air-dried, meth-
anol-fixed smears. Slides were viewed with a Leitz 
Ortholux microscope, and photographs were taken on 
Kodak Tri-X film. All cell counts represented averages 
of two separate experiments counting 100 cells each. 
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Sepharose-coupled M-MuLV virion proteins. A 
40-mg sample of unlabeled M-MuLV protein was de-
rived from virions that were purified from culture 
supernatant fluids by two cycles of sucrose gradient 
centrifugation in the MIT Cell Culture Center. The 
virions were lysed with 5% Triton X-100-0.5 M NaCl, 
dialyzed to pH 8.5 (100 mM NaHCOa), and coupled 
with 4 g of freeze-dried CNBr-activated Sepharose 4B 
(Pharmacia Fine Chemical Corp.) overnight at 4°C. 
[ 35S]methionine-labeled M-MuLV (1!f cpm) was 
added as a tracer. After washing, the final coupled 
protein was estimated at 2.5 mg/ml of swollen resin. 
RESULTS 
Production of an antiserum reactive with 
A-MuLV-specified P120 (anti-AbT). To de-
velop a syngeneic regressor system for produc-
tion of anti-A-MuLV sera, various cell line and 
mouse strain combinations were examined. The 
approach used involved injecting mice with live, 
in vitro-derived transformed lymphoid cells, 
monitoring the mice for tumor formation and 
subsequent rejection, and then challenging them 
with increasing cell doses. Activity against A-
MuLV-specified proteins was determined by di-
rect immunoprecipitation (see below). 
Initially, 15 independently derived A-MuLV-
transformed lymphoid cell lines of BALB/c ori-
gin were injected into syngeneic mice. Progres-
sive, disseminated tumors developed in the ma-
jority of the mice, a finding consistent with 
earlier reports (10, 17, 21). Use of low doses (loa 
cells per mouse) of nonproducer cells given in-
traperitoneally resulted in 100% mortality in 3 
weeks. When low doses of live or mitomycin C-
treated cells (injected subcutaneously) did not 
kill all of the animals, the survivors failed to 
reject increased doses of cells and did not pro-
duce a demonstrable response to A-MuLV pro-
teins. BALB/c-derived H-2k congenic mice re-
jected high doses (>106 cells per mouse) of 
BALB/c-derived nonproducer cells but did not 
respond to A-MuLV proteins. 
Because the BALB/c system proved unsuc-
cessful, lymphoid cell lines derived from SWR/ 
J, C57BRcd/J, C57BL6/J, and C57L/J mice 
were examined. Groups of 20 mice were injected 
with two SWR/J and one C57BRcd/J-derived 
cell line, and all of the mice tested succumbed to 
the initial inoculum. Even doses of 103 cells of 
the C57BRcd/J nonproducer cell line BR48 
killed most of the test animals in 3 to 4 weeks. 
C57BL6 mice, used to produce anti-Abelson sera 
by another laboratory (16), failed to reject a dose 
of 105 live syngeneic cells given subcutane-
ously. Forty percent (2/5) of the animals in-
jected intraperitoneally with 105 cells survived 
this dose and two subsequent challenges. The 
serum from these mice, however, reacted pre-
dominantly with helper virus-specified struc-
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tural proteins (data not shown). 
With C57L/J mice we were finally successful. 
C57L/J mice were injected subcutaneously with 
either a focus-derived syngeneic cell line desig-
nated L1 or a subclone of this cell line, L1-2, at 
doses of 105 or 5 X 105 live cells per animal. 
Eighty-five percent (12/14) of the L1-injected 
mice survived the initial dose, and 100% (5/5) of 
the initial L1-2 group and 90% (27 /30) of a larger 
second group survived. The initial inoculum 
grew in the mice as evidenced by the develop-
ment of small (1- to 3-cm) nodules at the injec-
tion site about 1 week postinoculation; these 
growths disappeared by 2 to 2.5 weeks postinjec-
tion. Animals surviving the initial cell dose re-
jected subsequent intraperitoneal challenges of 
up to 107 cells per mouse. 
Specificity of anti-Abelson tumor sera 
(anti-AbT): reactivity with P120. Serum 
samples collected from C57L/J animals 10 to 14 
days after the second and subsequent tumor 
challenge doses were tested for their immuno-
precipitation specificity. Extracts of 2M3/M 
cells (a BALB/c, A-MuLV-transformed, pro-
ducer cell line) pulse labeled for 30 min with 
( 35S]methionine were used as the test antigen. 
This cell line expresses both the A-MuLV-en-
coded P120 and the major structural protein 
precursors of the helper virus (M-MuLV). 
Screening of serum samples of individual mice 
taken after the second tumor challenge showed 
that all animals had a response to the P120 
protein of A-MuLV, but the intensity varied 
widely (Fig. 1). Animals numbered 1 to 12 were 
injected and boosted with cell line Ll, and num-
bers 13 to 17 were injected with subclone L1-2. 
The presence of detectable antibody reactive to 
the M-MuLV core precursor (Pr61rac) and en-
velope precursor (Prso•nv) varied but was more 
pronounced in the group injected with Ll. Dur-
ing repeated cycles of immunization, these dif-
ferences in precipitating antibody patterns were 
minimized and a common pattern of prominent 
response to P120 and Prso•nv and weak or absent 
response to Pr65Kac was found. Only antibody 
that could bind to the Staphylococcus aureus 
immune adsorbent was monitored in the above 
screenings, but subsequent testing of serum 
pools employing goat anti-mouse immunoglob-
ulin in a two-stage precipitation assay did not 
reveal any additional specificities (data not 
shown). Tests with e"S]methionine-labeled ex-
tracts of the L1 or L1- 2 cell lines also did not 
reveal any additional specificities or unusual 
quantitative differences between these A-
MuL V -transformed cell lines and those of other 
strains (data not shown). 
Lack of other A-MuL V -related products. 
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FIG. 1. Screening of anti·AbT sera from individ· 
ual mice. Mice of the C57L/J strain were inoculated 
with viable cells of the in vitro-transformed clonal 
lymphoid cell line L1 (mice no. 1 to 12) or a subclone, 
L1-2 (mice no. 13 to 17). Serum was harvested 12 days 
after the second inoculation, and 2.5·!Ll portions were 
tested by immunoprecipitation of extracts of 2M3/M 
cells labeled for 30 min with r 5S}methionine. Precip· 
itates were collected on S. aureus immunoadsorbent 
(7) and analyzed by electrophoresis through 10% poly· 
acrylamide-sodium dodecyl sulfate gels (B) developed 
by fluorography (2). 
To search for additional A-MuLV-specified pro-
teins that might lack methionine, we labeled A-
MuL V -transformed cells with a variety of pro-
tein precursors, or by chemical iodination tech-
niques, and used extracts of these labeled cells 
in direct immunoprecipitation assays with pools 
of anti-AbT serum. To simplify the analysis, we 
used A-MuLV-transformed, nonproducer cell 
lines, like 2M3, to direct attention to A-MuLV 
genome expression rather than that of the M-
MuLV helper virus. When 2M3 cells were pulse-
labeled (1 h) with [3H]leucine (Fig. 2A) or 14C-
mixed amino acids (Fig. 2C), or labeled for 18 h 
with [3H]leucine (Fig. 2B), the only reproducibly 
immunoprecipitable protein was the P120 pro-
tein. Similar tests were done using mouse and 
rat A-MuLV-transformed nonproducer fibro-
blast cultures with the same results. 
To further evaluate the specificities of the 
anti-AbT serum, and to search for putative A-
MuLV-related proteins that could have ex-
tremely low synthetic rates but be stable enough 
to accumulate within the cells, we used chemical 
iodination techniques. Lactoperoxidase-cata-
lyzed iodination labels available tyrosine and 
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Fw. 2. Specificities of anti-AbT serum tested on 
metabolically labeled cells. Normal mouse serum 
(lane 1) was compared to pooled anti-AbT serum 
(lane 2) for immunoprecipitation of proteins from (A) 
2M3 cells labeled for 1 h with rHJleucine; (B) 2M3 
cells labeled for 18 h with rHJleucine; (C) 2M3 cells 
labeled for 1 h with 14C-mixed amino acids; or (D) 
2M3/M cells labeledfor5 h with D-rHJglucosamine. 
Samples were analyzed as described in Fig. 1. 
histidine residues on peripheral membrane pro-
teins. It has been used to label the MuLV env 
gene product, gp70, on the virion and cell surface 
(6, 30, 31). A-MuLV-transformed nonproducer 
line 2M3 (Fig. 3, lane A) and its M-MuLV-su-
perinfected derivative 2M3/M (Fig. 3, lane B) 
were labeled to high specific activity, and ex-
tracts were immunoprecipitated with anti-AbT 
serum. Only gp70 on the producer cell line 2M3/ 
M was detected. Neither P120 or other potential 
A-MuLV proteins were labeled. 
We extended our studies to a reagent that 
could penetrate into cells and label proteins-
the Bolton-Hunter reagent. It reacts rapidly 
with free amino groups and will function at pH 
7.5 and low temperature. Intact 2M3 (Fig. 3C) 
and 2M3/M (Fig. 3D) cells were labeled at 0°C 
with 1251-labeled Bolton-Hunter reagent, 
washed, and extracted for immunoprecipitation 
with anti-AbT serum. P120 was now labeled in 
both cell lines, as were the Prso•nv and Pr61)6011 
precursors in the 2M3/M cells. No additional A-
MuLV-related proteins were detected. 
These studies do not rule out the possibility 
of an additional protein encoded by A-MuLV; 
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FIG. 3. Specificities of anti-AbT serum tested on 
chemically iodinated cells. Viable 2M3 cells (A) or 
2M3/M cells (B) were labeled with Na 125l by the 
lactoperoxidase technique, or, alternatively, 2M3 
cells (C) and 2M3/M cells (D) were labeled with the 
1251-labeled Bolton-Hunter reagent. Extracts were im-
munoprecipitated with anti-AbT serum, and precipi-
tates were analyzed as described in Fig. 1. 
they show, however, that the anti-tumor anti-
serum we have prepared strongly precipitates 
P120 and that P120 is the only A-MuLV -specific 
protein detected even when various metabolic 
and chemical labels are used. 
Lack of carbohydrate on P120. In several 
attempts, we have been unable to label P120 or 
any additional A-MuLV-related protein with 
sugar precursors of glycoproteins. When 2M3/ 
M cells (the nonproducer line superinfected with 
M-MuLV) were labeled with D-[3H]glucosamine 
for 5 h (Fig. 2D), the Prso•nv precursor was 
heavily labeled but P120 was not labeled. The 
faint band(s) at 90,000 to 95,000 molecular 
weight is the glycosylated form of the M-MuLV 
gag gene (gp9QIIac) similar to that described for 
other ecotropic MuLV strains (26). In other ex-
periments, [3H]mannose did not label P120. Fur-
thermore, P120 pulse-labeled with [35S]methio-
nine and isolated by immunoprecipitation was 
not sensitive to the action of endo-,8-N-acetyl-
glucosaminidase H, an enzyme that cleaves the 
high mannose structures from recently made 
glycoproteins and thus markedly changes their 
electrophoretic mobility (25, 32). Hence, no de-
tectable fraction of P120 undergoes carbohy-
drate addition. 
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Reactivity with the A-MuL V -specific por-
tion of P120. Because P120 shares serological 
determinants with the N-terminal gag gene 
products (p15, pl2, and part of p30), we per-
formed competition experiments to determine 
whether the anti-AbT serum contains antibodies 
reactive to the portion of Pl20 that shares no 
antigenicity with M-MuLV proteins (presum-
ably the C-terminal region of about 90,000 mo-
lecular weight). A [35S)methionine-labeled 2M3/ 
M cell extract was incubated either without com-
peting protein, or with 50 or 150 p.g of lysed M-
MuLV virions, and precipitated with a constant 
amount of normal mouse serum (Fig. 4A) or 
anti-AbT serum (Fig. 4B). Increasing amounts 
of the unlabeled M-MuLV proteins competed 
out the ability of the anti-AbT serum to precip-
itate Prso•nv and Pr6&'a11, but the P120 precipi-
tation was essentially unaffected. We have also 
been able to proteolytically cleave P120 into 
fragments that are precipitable with either anti-
gag gene product reagents or anti-AbT serum 
but not both (unpublished data). 
A-MuL V cell surface antigen. To test 
whether anti-AbT serum could react with a cell 
surface antigen on A-MuLV-transformed cells, 
we have used a two-stage immunofluorescence 
procedure with intact viable cells as our test 
antigen. Sera with specificity for the helper virus 
M-MuLV gene products gp70, p30, and p15 as 
well as anti-AbT serum have been tested on 
several A-MuLV-transformed nonproducer cell 
lines as well as on producer cells containing both 
the A-MuLV and M-MuLV gene products (sum-
marized in Table 1). 
Only the anti-AbT serum was able to stain 
the cell membrane of A-MuLV-transformed 
nonproducer lines such as 2M3 (Fig. 5). Sera 
with specificity to the gag gene-related portion 
of P120, like anti-p15 and anti-p30, although 
able to precipitate P120 from lysed cells (29), 
could not stain the surface of viable cells. Ab-
sorption of anti-AbT serum with M-MuLV pro-
teins coupled to Sepharose did not diminish the 
staining on A-MuLV-transformed nonproducer 
cells. 
Absorption of anti-AbT serum with one A-
MuL V -transformed nonproducer cell line, how-
ever, removed the ability to stain a second A-
MuL V nonproducer cell line. A 1:20 dilution of 
the pool of anti-AbT serum used in Fig. 5 was 
absorbed with intact, viable A2 cells (a trans-
formed NIH/3T3 fibroblast nonproducer). The 
absorbed serum and a control dilution were clar-
ified and assayed for their ability to stain the 
surface of 2M3 cells (a BALB/c lymphoid non-
producer cell) and 2M3/M (the M-MuL V -super-











FIG. 4. Demonstration of activity for the unique 
portion of P120 in anti-AbTserum. Extracts of 2M3! 
M cells labeled for 30 min with { 35S]methionine; cells 
were immunoprecipitated with 2.5 p.l of (A) normal 
mouse serum (NMS) or (B) anti-Abelson tumor serum 
(aAbT). Lane 1 had no competing protein; lane 2 had 
50 pg and lane 3 had 150 pg of M-MuLV virion 
proteins included in the lysate. Samples were col-
lected and analyzed as described in Fig. 1. 
sorbed serum was markedly reduced in its ability 
to stain the nonproducer cell line 2M3, which 
expresses only P120, but retained the ability to 
stain the M-MuLV-superinfected 2M3/M line, 
which also expresses at the cell membrane the 
M-MuLV env gene products gp70 and p15E. 
This difference was reflected in residual immu-
noprecipitation capability of the control and ab-
sorbed anti-AbT serum. Because A2 cells do not 
express the M-MuLV env gene, after absorption 
with these cells there was no detectable differ-
ence in the ability of anti-AbT serum to precip-
itate the Prso•nv precursor from 2M3/M cells 
(Fig. 6C). Absorption with A2 cells, however, 
caused a marked decrease in precipitating anti-
body for Pl20; after absorption only 10 to 20% 
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TABLE 1. Cell surface fluorescence on A-MuL V-transformed cells a 
Percent of fluorescent cells in cell line• 
Serum 
A2 AbNRK 2M3 2M3/M 
Normal mouse serum <1 <1 <1 <1 
Anti-AbT >95 (++) >95 (+++) >95 (+++) >95 (++++) 
Anti-AbT absorbed with >95 (++) >95 (++) >95 (+++) >95 (+++) 
M-MuLV proteins cou-
pled to Sepharosec 
Normal rabbit serum <1 <1 <1 <1 
Rabbit anti-M-MuLV p15/ <1 N-rt 2 (+) 75 (+) 
reverse transcriptase 
Rabbit anti-M-MuLV p30 <1 NT <1 >95 (++) 
Rabbit anti-M-MuLV gp70 <1 <1 <1 >95 (++++) 
a Viable .cells (1<f to 2 x 1<f) were stained for cell surface antigens in suspension at 4 °C with 50 ,U. of normal 
or immune serum at a final 1:20 dilution. Fluoresceinated goat anti-mouse or goat anti-rabbit immunoglobulin 
G (Meloy Labs) at 1:15 and 1:40 dilutions, respectively, were used for the second stage. Wet mounts and air-
dried, methanol-fixed smears were counted (minimum of 100 cells each) to determine a percentage of positive 
staining. A subjective quantitation of+ (dull) to ++++ (very bright) is shown. 
b Cell lines: A2, NIH/3T3 nonproducer; AbNRK, normal rat kidney nonproducer; 2M3, BALB/c lymphoid 
nonproducer; 2M3/M, 2M3 superinfected with M-MuLV. 
c A 1-ml sample of 1:10-diluted anti-AbTwas mixed with 2 ml of wet packed Sepharose 2B coupled with lysed 
M-MuLV proteins (2.5 mg of final protein bound per ml of Sepharose) for 6 h at 4 °C. The serum was recovered 
by centrifugation and reclarified before use. 
of the precipitating activity for P120 was left in 
different pools (the residual P120 in lane 3, Fig. 
6C, is not evident in the print but was detectable 
on the autoradiogram). Therefore, a variable 
portion of the antibody to P120 may be reactive 
with determinants that are not accessible at the 
cell surface, but the majority could be absorbed 
by live cells. Similar absorption experiments us-
ing M-MuLV-infected NIH/3T3 cells or M-
MuLV-infected Moloney sarcoma virus-trans-
formed cells did not remove anti-P120 activity 
from the anti-AbT serum. 
In separate experiments (data not shown), we 
found that P120 in intact cells was resistant to 
digestion with the proteases trypsin and chy-
motrypsin under conditions that previously were 
shown to remove peripheral proteins like gp70 
(30). Such protease treatment did not diminish 
the ability of anti-AbT serum to stain A-MuLV-
transformed cells. 
Thus, it is likely that P120, or perhaps a 
fraction of the P120 molecules, exposes a portion 
of its 90,000-molecular weight unique region 
above the cell membrane but that other regions 
of the molecule, including the gag gene-related 
amino terminus, are buried in or beneath the 
lipid bilayer and not accessible to antibody mol-
ecules. The external region is not, however, de-
tectably labeled by lactoperoxidase-catalyzed io-
dination and is not as protease sensitive as a 
peripheral membrane protein like gp70. 
DISCUSSION 
In the process of rejecting syngeneic tumors 
caused by A-MuLV-transformed cells, C57L/J 
mice make a humoral antibody response to the 
A-MuLV-specified P120 protein. No other A-
MuLV-specific protein is detected by such sera, 
and much of the antibody is directed to the A-
MuLV-specific region of P120. The serum de-
tects cell surface antigen by live-cell staining in 
a two-stage immunofluorescence test. Because 
P120 is the only A-MuLV protein reactive with 
the serum, the results imply that at least part of 
the A-MuLV-specific region of P120 is exposed 
on the cell surface. The ability of intact cells to 
absorb much of the reactivity to P120 also argues 
that the protein is partly exposed on the cell 
surface. 
P120 is not, however, a classic cell surface 
protein. It does not detectably label with car-
bohydrate precursors, it is not labeled by lacto-
peroxidase-catalyzed iodination, it is not cleaved 
by mild external treatment of cells with protease, 
and its mobility is not affected by treatment 
with endoglycosidase H. By contrast, gp70 of 
MuL V has readily detectable carbohydrate, is 
iodinated, and is cleaved by protease, and the 
electrophoretic mobility of its intracellular form 
is increased by endoglycosidase H treatment (6, 
30-32). Many other peripheral membrane pro-
teins also have this set of characteristics. No 
good model exists for a non-glycosylated protein 
that is exposed on the cell surface. It is signifi-
cant, however, that the feline oncornavirus-as-
sociated cell membrane antigen (FOCMA) of 
feline sarcoma virus has many properties in com-
mon with the A-MuLV P120 (20, 24) and is not 
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FIG. 5. Detection of an A-MuL V cell surface antigen by immunofluorescence. Intact, viable 2M3 cells, a 
clonally derived BALB!c A-MuL V-transformed lymphoid cell line, were tested in a two-stage immunofluo· 
rescence assay (see the text) employing normal mouse serum (NMS) or anti·AbT serum (aAbT) at a final 
dilution of 1:20. After unbound antibody was washed away, fluoresceinated goat anti-mouse immunoglobulin 
G at 1:15 final dilution was used and wet mounts were photographed. (a) Cells treated with normal mouse 
serum (NMS), phase contrast; (b) cells treated with normal mouse serum, fluorescence; (c) cells treated with 
anti-AbT serum, phase contrast; (d) cells treated with anti·AbT serum, fluorescence. Specific fluorescent 
staining in (d) is seen as small clusters or caps on the outer cell surface. Nonspecific homogeneous staining 
of a single dead cell is seen in (b). 
glycosylated (Worley and Essex, personal com-
munication). FOCMA is a surface antigen that 
is synthesized as part of a protein containing 
both gag determinants and a unique region. 
Also, a non-glycosylated adenovirus-simian vi-
rus 40 fusion protein is thought to be expressed 
at the cell surface (4) and may be important as 
a transplantation antigen. 
It is curious that only C57L/J mice efficiently 
reject syngeneic A-MuLV-transformed cells. It 
is not known whether their ability to make anti-
AbT antibody is related to their rejection ability. 
To date we have found no unique feature of the 
C57L/J strain or their A-MuLV-transformed 
cells that can explain the efficient tumor regres-
sion we have observed. Risser et al. (15) have 
described two genetic loci that control the rela-
tive resistance to A-MuLV tumor induction. 
C57L/ J is among the resistant strains, but so are 
C57BR/cdJ and C57BL6/J, which we found 
much less efficient at rejecting syngeneic tumor 
challenge. C57L/ J transformed cell lines showed 
no qualitative or quantitative difference in the 
level or pattern of expression of either the A-
MuLV P120 or M-MuLV proteins that we have 
yet discerned. 
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FIG. 6. Absorption of anti-AbT cell surface reactivity with transformed nonproducer cells. Dilutions of 
anti-AbT serum, unabsorbed control (0) or absorbed with viable, intact A2 cells (A-MuL V-transform.ed NIH/ 
3T3 nonproducer cell line) (e) were used to surface stain viable 2M3 cells (A) and 2M3 1M cells (B). Absorption 
was carried out in three sequential cycles using 1 ml of 1 :20-diluted serum, 3 x 108 cells per cycle, and a 45-
min exposure at 0° C. The percentage of positive cells and a visual estimate of average fluorescence intensity 
(+ =dull; ++++ = very bright) were plotted and compared to staining with normal mouse serum (0). (C) 
Immunoprecipitation of 2M3/ M cells labeled with r"S]methionine for 30 min. Equivalent amounts of normal 
mouse serum (lane 1), control unabsorbed anti-AbT serum (lane 2), and absorbed anti-AbT serum (lane 3). 
Sample analysis was as described in Fig. 1. 
The A-MuLV genome consists of a 5,600-base 
RNA of which about 3,600 bases are A-MuLV 
specific and 2,000 bases are derived from M-
MuLV (Shields, Ph.D. thesis). P120 is encoded 
by about 2,700 bases of the A-MuLV-specific 
region, leaving 900 bases plus some of the M-
MuL V sequences as regions that could poten-
tially encode more A-MuLV-related proteins. 
Use of a second reading frame could make more 
coding potential available. It is not possible to 
exclude the existence of a second A-MuLV -spec-
ified protein, but no antiserum, whether anti-
AbT or anti-M-MuLV, has consistently revealed 
a second protein. Thus, it appears on present 
evidence that the A-MuLV genome encodes a 
single polypeptide and, assuming that A-MuLV 
transforms through the action of a protein, P120 
must be responsible for transforming cells. 
Whether the presence of part of P120 exposed 
on the cell surface is an aspect of its transforming 
activity remains to be demonstrated. 
Risser et al. (16) have reported an Abelson 
tumor cell surface antigen detected by a cyto-
toxicity-absorption assay and have shown the 
presence of a cross-reacting antigen in normal 
lymphoid tissues (particularly bone marrow) of 
BALB/c mice and closely related strains. 
Whether the antigenic specificity(ies) monitored 
in those studies is identical to the anti-P120 
activity defined in the present analysis is not 
clear. 
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